BioCryst Pharma (BCRX) Priced 5M Common Offering at $9.75/Share
More News related to BCRX
- BioCryst Pharma (BCRX) Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
- BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
- Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
- BioCryst To Present At 12th Annual BIO CEO & Investor Conference
- Notable Analyst Rating Changes 1/29: WMT, BCR, MAN, URBN, ARBA Upgraded; FII, BHLB, KSP Downgraded
More News related to Equity Offerings
- China Agritech (CAGC) Files $100M Mixed Securities Shelf
- ChinaTel Group (CHTL) Jumps Higher On 'Above-Market' Equity Financing
- Developers Diversified Realty (DDR) Prices 37.3M Common Offering at $8.16/Share
- EV Energy Partners (EVEP) Prices 3M Common Unit Offering at $28.08/Unit
- Toreador Resources (TRGL) Prices 3M Shares at $8.50/Share
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. All of the shares are being offered by BioCryst pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. BioCryst has also granted the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any.
Morgan Stanley is acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers. The offering is expected to close on November 25, 2009.
Related Categories
Equity OfferingsStocks Mentioned
-0.33Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
